Compare JPMorgan Ultra Short Income ETF (JPST) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Twist Bioscience Corp — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.47, while Twist Bioscience Corp trades at $122.96 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| JPST | TWST | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $50.78 | $124.88 |
52-Week Low | $50.40 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% daily, with a bearish technical signal driven by moving averages. The fund focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends, including recent $0.17 payouts. Institutional holdings have increased, as seen in 13F filings from Financial Management Professionals Inc. and Ashton Thomas Securities LLC in Q2 2026, indicating steady investor interest amid a rising rate environment.
The outlook for JPST is stable, benefiting from its low-risk profile in volatile markets, but faces headwinds from potential Fed rate hikes that could pressure short-term bond yields. Risks include interest rate sensitivity and inflation concerns, yet it remains a core holding for conservative investors seeking yield with minimal volatility.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
